Twist Bioscience Corp (TWST): Capital Expenditures

Annual figures by period end, from SEC filings.

$47.58M
Year ended 2026-09-30
+19.6%
3-year compound annual growth
+11.9%
5-year compound annual growth
$101.86M2017-09-30: $6.59M2018-09-30: $3.69M2019-09-30: $14.76M2020-09-30: $9.87M2021-09-30: $27.06M2022-09-30: $101.86M2023-09-30: $27.78M2024-09-30: $5.08M2025-09-30: $28.00M2026-09-30: $47.58M$47.58M
2017-09-30 Capital Expenditures (USD) 2026-09-30
Period endedCapital ExpendituresChange YoYSource filing
2026-09-30$47.58M+69.9%2026-11-16, From 2025-10-01
2025-09-30$28.00M+451.7%2026-11-16, From 2024-10-01
2024-09-30$5.08M-81.7%2026-11-16, From 2023-10-01
2023-09-30$27.78M-72.7%2025-11-17, From 2022-10-01
2022-09-30$101.86M+276.4%2024-11-18, From 2021-10-01
2021-09-30$27.06M+174.2%2023-11-21, From 2020-10-01
2020-09-30$9.87M-33.1%2023-06-05, From 2019-10-01
2019-09-30$14.76M+300.1%2021-11-23, From 2018-10-01
2018-09-30$3.69M-44.1%2020-11-27, From 2017-10-01
2017-09-30$6.59Mn/a2019-12-13, From 2016-10-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Twist Bioscience Corp (TWST)2026-09-30$47.58M+69.9%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$9.86M+529.2%
ADMA Biologics, Inc. (ADMA)2025-12-31$22.57M+174.4%
Immunocore Holdings plc (IMCR)2025-12-31$4.34M-16.1%
Krystal Biotech, Inc. (KRYS)2025-12-31$11.95M+182.0%
Repligen Corp (RGEN)2025-12-31$23.52M-8.4%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$2.96M-19.2%
Vericel Corp (VCEL)2025-12-31$27.16M-57.5%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$33.84M+205.7%

Compare TWST, TARS, ADMA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗